Carcino3D™ technology is developed from patient biopsies, whole blood, and immune cells with a heterogenous population of cells isolated directly from the biopsy and a detailed characterised patient profile with sequencing and mutation data available. These printed patient tumours are available in 96 or 384 well formats with tumour specific ECM and can also include tumour infiltrating lymphocytes (T cells, B cells, NK cells etc) and tumour associated macrophages. As per request, we can also develop vascularised and irradiated tumours for combination therapies.
Available Carcino3D™ Printed Tumours
CarcinoGBM™ are the 3D bioprinted models of the glioblastoma microenvironment, offering a platform for in vitro high-throughput, accurate and rapid drug discovery and screening for novel, combinatorial, and repurposed drugs. Our models can be used for drug efficacy, drug pathway, and toxicity testing and are bioengineered to de-risk cancer drug discovery, offering translational data with respect to cancer heterogeneity and microenvironments. We offer 2 different types of CarcinoGBM models:
CarcinoGBM™ Basic model: Digital microscope images, taken of the growing constructs which are entirely bioprinted.